Retatrutide (research designation LY3437943) is among the most-studied compounds in metabolic research today, and the headline of G13’s GLP research category.
Classification
Retatrutide is a triple receptor agonist — it targets the GLP-1, GIP, and glucagon receptors at once. That three-receptor profile distinguishes it from single agonists like Semaglutide (GLP-1 only) and dual agonists like Tirzepatide (GIP/GLP-1).
In research
It is studied in metabolic-pathway and energy-regulation research, where the combined receptor activity lets researchers examine multiple incretin pathways together. This describes mechanism for research reference only — not outcomes or any application.
Specifications & verification
G13 supplies Retatrutide as a 10mg lyophilized vial, produced to a ≥99% purity standard; store at -20°C, protected from light and moisture. Every batch ships with an independent, lot-matched HPLC Certificate of Analysis (current lot CS-re10920) — verify it before or after ordering. New to COAs? See How to Read a Peptide COA.
Retatrutide is a research reference material for laboratory research use only. Not for human consumption.